Fig. 7.

Examination of the effect of chemo-switching. a Gemcitabine treatment (58 mg/kg, 2× per week, ip) showed significant improvement in survival in mice implanted with either SKOV-3-13 or 7SD (P < 0.05; n = 5 for control and gemcitabine treatment). b Doxorubicin treatment (2 mg/kg, day 1 and 5; 21 day cycles) mediated a minimal but statistically significant improvement in survival in mice implanted with either SKOV-3-13 (P < 0.05; n = 5 for control and doxorubicin treatment). A minimal improvement in survival was noted in mice implanted with 7SD and treated with doxorubicin (51 and 47 days for treatment and control groups), however, this did not reach statistical significance